Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

Blood Group Antigen Lewis B Antibody [2-25LE; same as LWB01]

In Stock
Catalog Number Formulation Size Price
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunofluorescence (IF)
Immunohistochemistry (IHC)
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes


The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Lewis blood group antigens are carbohydrate moieties structurally integrated in mucous secretions. Lewis antigen system alterations have been described in gastric carcinoma and associated lesions. Anomalous expression of Lewis B antigen has been found in some non-secretory gastric carcinomas and colorectal cancers.

Product Properties & Targets

Antibody Type
Species Reactivity
Research Areas
Isotype / Light Chain
IgG1 / Kappa
Cellular Localization
Golgi apparatus, Golgi stack membrane
Gene Name
Positive Control
Mucin isolated from a human ovarian cyst fluid
Alternate Names
3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3, 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase, Alpha-3-fucosyltransferase FUT3, Blood group Lewis alpha-4-fucosyltransferase, Fucosyltransferase 3, Fucosyltransferase III, Blood group Lewis alpha-4-fucosyltransferase; Fucosyltransferase 3; Fucosyltransferase III; FucT-III; FUT3; Galactoside 3(4)-L-fucosyltransferase; gastric mucin; leB; lewis antigen system; lewis B blood group antigen; Lewis FT; major airway glycoprotein

Database Links

Entrez Gene ID

Additional Information

2-25LE; same as LWB01
Chromosome Location
Mol. Weight of Antigen


  • Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to both the subterminal N-acetyl glucosamine (GlcNAc) of type 1 chain (beta-D-Gal-(1->3)-beta-D-GlcNAc) glycolipids and oligosaccharides via an alpha(1,4) linkage, and the subterminal glucose (Glc) or GlcNAc of type 2 chain (beta-D-Gal-(1->4)-beta-D-GlcNAc) oligosaccharides via an alpha(1,3) linkage, independently of the presence of terminal alpha-L-fucosyl-(1,2) moieties on the terminal galactose of these acceptors and participates in the blood groups Lewis determination and expression of Lewis a (Le(a)), lewis b (Le(b)), Lewis x/SSEA-1 (Le(x)) and lewis y (Le(y)) antigens (PubMed:12668675, PubMed:1977660, PubMed:11058871). Also catalyzes the transfer of L-fucose to subterminal GlcNAc of sialyl- and disialyl-lactotetraosylceramide to produce sialyl Lewis a (sLe(a)) and disialyl Lewis a via an alpha(1,4) linkage and therefore may regulate cell surface sialyl Lewis a expression and consequently regulates adhesive properties to E-selectin, cell proliferation and migration (PubMed:12668675, PubMed:11058871, PubMed:27453266). Catalyzes the transfer of an L-fucose to 3'-sialyl-N-acetyllactosamine by an alpha(1,3) linkage, which allows the formation of sialyl-Lewis x structure and therefore may regulate the sialyl-Lewis x surface antigen expression and consequently adhesive properties to E-selectin (PubMed:11058871, PubMed:29593094). Prefers type 1 chain over type 2 acceptors (PubMed:7721776). Type 1 tetrasaccharide is a better acceptor than type 1 disaccharide suggesting that a beta anomeric configuration of GlcNAc in the substrate is preferred (PubMed:7721776). Lewis-positive (Le(+)) individuals have an active enzyme while Lewis-negative (Le(-)) individuals have an inactive enzyme (PubMed:1977660).

Key References

  • Richman, P.I. et al. 1987. Monoclonal antibodies to human colorectal epithelium: markers for differentiation and tumour characterization. Int. J. Cancer. 39: 317-328.
  • Rouger, P.h., et al, eds. 1987. Proceedings of the first international work- shop on monoclonal antibodies against human red blood cells and related antigens (Paris, 1987). Blood Transfusion Immunohaematology 30: 353- 720.
  • Torrado J, Correa P, Ruiz B, Bernardi P, Zavala D, Bara J. Lewis antigen alterations in gastric cancer precursors. Gastroenterology. 1992 Feb;102(2):424-30.
  • Bara, J. et al. 1988. Immunochemical characterization of mucins. Polypeptide (M1) and polysaccharide (A and Leb) antigens. Biochem. J. 254: 185-193.
  • Creuzot-Garcher C, Guerzider V, Assem M, Bron AM, Delannoy P, Bara. Alteration of sialyl Lewis epitope expression in pterygium. J.Invest Ophthalmol Vis Sci. 1999 Jul;40(8):1631.

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.


This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.


There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.


There are no reviews yet.

Be the first to review “Blood Group Antigen Lewis B Antibody”

Your email address will not be published. Required fields are marked *


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.